Cirrustx
Cambridge, US · 12 employees on LinkedIn · 1 known investors
Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy. It serves patients with chronic blinding eye diseases and operates from Cambridge, Massachusetts and Singapore.
Founders & leadership
YK
Ying Kai ChaninCo-founder & CEO
Investors · 1
Frequently asked questions
- What does Cirrustx do?
- Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy. It serves patients with chronic blinding eye diseases and operates from Cambridge, Massachusetts and Singapore.
- Who founded Cirrustx?
- Cirrustx was founded by Ying Kai Chan.
- Who are Cirrustx's investors?
- Cirrustx's investors include ZAKA VC.
- Where is Cirrustx headquartered?
- Cirrustx is headquartered in Cambridge, US.